Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexycu for Postoperative Inflammation in Cataract Surgery
NCT06497699Phase 4Completed
- Sponsor
- Ocumension Biotech
- Start
- Oct 2021
- Primary completion
- Jul 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of IBI-10090 in post-operative inflammation, sponsored by Ocumension Biotech. Started Oct 2021; status: completed.
02
Drugs
IBI-10090
03
Conditions
post-operative inflammation
Beyond the preview
Go deeper on NCT06497699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06497699.